Published in Cell Stem Cell on May 08, 2009
Cancer stem cells: impact, heterogeneity, and uncertainty. Cancer Cell (2012) 5.44
Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell (2014) 4.04
Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell (2010) 3.82
Notch promotes radioresistance of glioma stem cells. Stem Cells (2010) 3.07
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 2.98
Malignant glioma: lessons from genomics, mouse models, and stem cells. Cell (2012) 2.85
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
Understanding cancer stem cell heterogeneity and plasticity. Cell Res (2012) 2.39
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Quiescent sox2(+) cells drive hierarchical growth and relapse in sonic hedgehog subgroup medulloblastoma. Cancer Cell (2014) 2.30
Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med (2012) 2.21
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Non-stem cell origin for oligodendroglioma. Cancer Cell (2010) 1.95
Cancer stem cells in glioblastoma. Genes Dev (2015) 1.91
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
c-Met signaling induces a reprogramming network and supports the glioblastoma stem-like phenotype. Proc Natl Acad Sci U S A (2011) 1.75
From the Cover: Neutralization of terminal differentiation in gliomagenesis. Proc Natl Acad Sci U S A (2013) 1.71
Imp2 controls oxidative phosphorylation and is crucial for preserving glioblastoma cancer stem cells. Genes Dev (2012) 1.64
Chemoresistance of glioblastoma cancer stem cells--much more complex than expected. Mol Cancer (2011) 1.64
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
In vitro generation of human cells with cancer stem cell properties. Nat Cell Biol (2011) 1.61
Potential therapeutic implications of cancer stem cells in glioblastoma. Biochem Pharmacol (2010) 1.60
Distribution of CD133 reveals glioma stem cells self-renew through symmetric and asymmetric cell divisions. Cell Death Dis (2011) 1.59
Evidence for label-retaining tumour-initiating cells in human glioblastoma. Brain (2011) 1.48
Cancer stem cells in glioblastoma--molecular signaling and therapeutic targeting. Protein Cell (2010) 1.45
Reactive oxygen species in cancer stem cells. Antioxid Redox Signal (2012) 1.44
The linker histone H1.0 generates epigenetic and functional intratumor heterogeneity. Science (2016) 1.44
Current strategies for identification of glioma stem cells: adequate or unsatisfactory? J Oncol (2012) 1.40
Cancer vaccines and carbohydrate epitopes. Vaccine (2011) 1.40
Prevention against diffuse spinal cord astrocytoma: can the Notch pathway be a novel treatment target? Neural Regen Res (2015) 1.39
An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma. Cell Rep (2013) 1.35
Cancer stem cells: cell culture, markers, and targets for new therapies. J Cell Biochem (2009) 1.35
Conversion of differentiated cancer cells into cancer stem-like cells in a glioblastoma model after primary chemotherapy. Cell Death Differ (2014) 1.32
Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev (2013) 1.31
BuGZ is required for Bub3 stability, Bub1 kinetochore function, and chromosome alignment. Dev Cell (2014) 1.28
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors. BMC Cancer (2010) 1.26
The brain microenvironment preferentially enhances the radioresistance of CD133(+) glioblastoma stem-like cells. Neoplasia (2012) 1.23
Therapeutic potential of AZD1480 for the treatment of human glioblastoma. Mol Cancer Ther (2011) 1.22
Glioblastoma multiforme: State of the art and future therapeutics. Surg Neurol Int (2014) 1.18
Telomestatin impairs glioma stem cell survival and growth through the disruption of telomeric G-quadruplex and inhibition of the proto-oncogene, c-Myb. Clin Cancer Res (2012) 1.17
Brain tumor stem cells: Molecular characteristics and their impact on therapy. Mol Aspects Med (2013) 1.14
Inconsistent immunohistochemical expression patterns of four different CD133 antibody clones in glioblastoma. J Histochem Cytochem (2011) 1.14
A molecular screening approach to identify and characterize inhibitors of glioblastoma stem cells. Mol Cancer Ther (2011) 1.13
Side population in human glioblastoma is non-tumorigenic and characterizes brain endothelial cells. Brain (2013) 1.12
Implications of cancer stem cell theory for cancer chemoprevention by natural dietary compounds. J Nutr Biochem (2011) 1.10
The cancer stem cell paradigm: a new understanding of tumor development and treatment. Expert Opin Ther Targets (2010) 1.09
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09
Differential analysis of glioblastoma multiforme proteome by a 2D-DIGE approach. Proteome Sci (2011) 1.08
Cisplatin restores TRAIL apoptotic pathway in glioblastoma-derived stem cells through up-regulation of DR5 and down-regulation of c-FLIP. Cancer Invest (2011) 1.08
Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov (2012) 1.07
Astrocytes enhance the invasion potential of glioblastoma stem-like cells. PLoS One (2013) 1.06
Mitochondrial control by DRP1 in brain tumor initiating cells. Nat Neurosci (2015) 1.06
Microenvironmental regulation of glioblastoma radioresponse. Clin Cancer Res (2010) 1.05
The development of cutaneous neurofibromas. Am J Pathol (2011) 1.04
Targeting glioma stem cells: a novel framework for brain tumors. Cancer Sci (2011) 1.03
Erythropoietin Receptor Signaling Through STAT3 Is Required For Glioma Stem Cell Maintenance. Genes Cancer (2010) 1.03
The raccoon polyomavirus genome and tumor antigen transcription are stable and abundant in neuroglial tumors. J Virol (2014) 1.03
Glioblastomas are composed of genetically divergent clones with distinct tumourigenic potential and variable stem cell-associated phenotypes. Acta Neuropathol (2013) 1.03
Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. PLoS One (2012) 1.02
miR-33a promotes glioma-initiating cell self-renewal via PKA and NOTCH pathways. J Clin Invest (2014) 1.02
Glycosphingolipid functions. Cold Spring Harb Perspect Biol (2011) 1.02
What is the clinical value of cancer stem cell markers in gliomas? Int J Clin Exp Pathol (2013) 1.02
Radioresistance of glioma stem cells: intrinsic characteristic or property of the 'microenvironment-stem cell unit'? Mol Oncol (2011) 1.01
Emerging treatment strategies for glioblastoma multiforme. EMBO Mol Med (2014) 1.00
Biological and clinical relevance of stem cells in pancreatic adenocarcinoma. J Gastroenterol Hepatol (2012) 1.00
Signaling in malignant astrocytomas: role of neural stem cells and its therapeutic implications. Clin Cancer Res (2009) 1.00
A single intravenous injection of oncolytic picornavirus SVV-001 eliminates medulloblastomas in primary tumor-based orthotopic xenograft mouse models. Neuro Oncol (2010) 1.00
Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest (2012) 0.98
DNMT-dependent suppression of microRNA regulates the induction of GBM tumor-propagating phenotype by Oct4 and Sox2. Oncogene (2014) 0.98
Clinically relevant doses of chemotherapy agents reversibly block formation of glioblastoma neurospheres. Cancer Lett (2010) 0.98
The Human Glioblastoma Cell Culture Resource: Validated Cell Models Representing All Molecular Subtypes. EBioMedicine (2015) 0.97
Glioblastoma cancer stem cells: Biomarker and therapeutic advances. Neurochem Int (2014) 0.96
Cancer stem cells in basic science and in translational oncology: can we translate into clinical application? J Hematol Oncol (2015) 0.96
The mTORC1/mTORC2 inhibitor AZD2014 enhances the radiosensitivity of glioblastoma stem-like cells. Neuro Oncol (2013) 0.96
What makes cancer stem cell markers different? Springerplus (2013) 0.96
Ionizing radiation in glioblastoma initiating cells. Front Oncol (2013) 0.95
Twisted tango: brain tumor neurovascular interactions. Nat Neurosci (2011) 0.95
Meiotic competent human germ cell-like cells derived from human embryonic stem cells induced by BMP4/WNT3A signaling and OCT4/EpCAM (epithelial cell adhesion molecule) selection. J Biol Chem (2012) 0.94
CD166/activated leukocyte cell adhesion molecule is expressed on glioblastoma progenitor cells and involved in the regulation of tumor cell invasion. Neuro Oncol (2011) 0.94
Targeting metabolism to induce cell death in cancer cells and cancer stem cells. Int J Cell Biol (2013) 0.94
Cancer stem cells and their mechanism of chemo-radiation resistance. Int J Stem Cells (2009) 0.94
Glioma stem cell maintenance: the role of the microenvironment. Curr Pharm Des (2011) 0.93
Transcriptional differences between normal and glioma-derived glial progenitor cells identify a core set of dysregulated genes. Cell Rep (2013) 0.93
Membrane glycolipids in stem cells. FEBS Lett (2009) 0.93
Contributions to drug resistance in glioblastoma derived from malignant cells in the sub-ependymal zone. Cancer Res (2014) 0.93
Salivary gland cancer stem cells. Oral Oncol (2013) 0.92
Elevating SOX2 levels deleteriously affects the growth of medulloblastoma and glioblastoma cells. PLoS One (2012) 0.92
Seeing is believing: are cancer stem cells the Loch Ness monster of tumor biology? Stem Cell Rev (2011) 0.92
MiR-215 Is Induced Post-transcriptionally via HIF-Drosha Complex and Mediates Glioma-Initiating Cell Adaptation to Hypoxia by Targeting KDM1B. Cancer Cell (2016) 0.92
Abrogation of radioresistance in glioblastoma stem-like cells by inhibition of ATM kinase. Mol Oncol (2014) 0.91
Phosphoproteome of human glioblastoma initiating cells reveals novel signaling regulators encoded by the transcriptome. PLoS One (2012) 0.91
Stemness in human thyroid cancers and derived cell lines: the role of asymmetrically dividing cancer stem cells resistant to chemotherapy. J Clin Endocrinol Metab (2014) 0.91
Inhibition of EGFR induces a c-MET-driven stem cell population in glioblastoma. Stem Cells (2014) 0.91
Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. Cell Death Differ (2014) 0.90
FoxM1 Promotes Stemness and Radio-Resistance of Glioblastoma by Regulating the Master Stem Cell Regulator Sox2. PLoS One (2015) 0.90
Brain cancer stem cells: current status on glioblastoma multiforme. Cancers (Basel) (2011) 0.90
Functional analysis of HOXD9 in human gliomas and glioma cancer stem cells. Mol Cancer (2011) 0.90
Cancer stem cell subsets and their relationships. J Transl Med (2011) 0.89
Understanding glioma stem cells: rationale, clinical relevance and therapeutic strategies. Expert Rev Neurother (2013) 0.89
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol (2008) 8.79
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain. Cancer Cell (2006) 8.09
microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res (2008) 4.81
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol (2008) 4.39
Epigenetic-mediated dysfunction of the bone morphogenetic protein pathway inhibits differentiation of glioblastoma-initiating cells. Cancer Cell (2008) 3.87
Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res (2005) 3.63
Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res (2009) 3.58
Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest (2008) 2.79
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
High-resolution global genomic survey of 178 gliomas reveals novel regions of copy number alteration and allelic imbalances. Cancer Res (2006) 2.56
A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2006) 2.49
Phase III study of enzastaurin compared with lomustine in the treatment of recurrent intracranial glioblastoma. J Clin Oncol (2010) 2.45
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res (2006) 2.44
Unsupervised analysis of transcriptomic profiles reveals six glioma subtypes. Cancer Res (2009) 2.42
Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell (2013) 2.38
Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas. Mol Cancer Res (2008) 2.22
Development of a T1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem Int Ed Engl (2007) 2.19
Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-kappaB, and glucose regulation. Cancer Res (2008) 2.16
Nonreceptor tyrosine kinase BMX maintains self-renewal and tumorigenic potential of glioblastoma stem cells by activating STAT3. Cancer Cell (2011) 2.04
Leptomeningeal carcinomatosis in non-small-cell lung cancer patients: impact on survival and correlated prognostic factors. J Thorac Oncol (2013) 1.93
Primary central nervous system lymphoma: time to ask the question. J Clin Oncol (2002) 1.92
Effect of brain- and tumor-derived connective tissue growth factor on glioma invasion. J Natl Cancer Inst (2011) 1.86
The neuronal microRNA miR-326 acts in a feedback loop with notch and has therapeutic potential against brain tumors. J Neurosci (2009) 1.85
Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest (2004) 1.85
Glioma stem cell proliferation and tumor growth are promoted by nitric oxide synthase-2. Cell (2011) 1.77
Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood (2004) 1.76
Recognition of glioma stem cells by genetically modified T cells targeting EGFRvIII and development of adoptive cell therapy for glioma. Hum Gene Ther (2012) 1.75
Prognostic significance of c-Met expression in glioblastomas. Cancer (2009) 1.68
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol (2009) 1.66
Cancer stem cells in gliomas: identifying and understanding the apex cell in cancer's hierarchy. Glia (2011) 1.63
History of allergies and autoimmune diseases and risk of brain tumors in adults. Int J Cancer (2002) 1.62
Predicting in vitro drug sensitivity using Random Forests. Bioinformatics (2010) 1.59
Relationship between malignant subtypes of meningioma and clinical outcome. J Clin Neurosci (2007) 1.58
Atypical spontaneous intracranial hypotension (SIH) with nonorthostatic headache. Headache (2007) 1.58
DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol (2009) 1.51
Reproductive and hormonal factors and risk of brain tumors in adult females. Int J Cancer (2005) 1.50
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol (2011) 1.50
Double antiangiogenic protein, DAAP, targeting VEGF-A and angiopoietins in tumor angiogenesis, metastasis, and vascular leakage. Cancer Cell (2010) 1.47
Phase II trial of pazopanib (GW786034), an oral multi-targeted angiogenesis inhibitor, for adults with recurrent glioblastoma (North American Brain Tumor Consortium Study 06-02). Neuro Oncol (2010) 1.46
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep (2013) 1.44
Talampanel with standard radiation and temozolomide in patients with newly diagnosed glioblastoma: a multicenter phase II trial. J Clin Oncol (2009) 1.41
Inhibitor of differentiation 4 drives brain tumor-initiating cell genesis through cyclin E and notch signaling. Genes Dev (2008) 1.34
Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol (2004) 1.33
Notch-1 regulates transcription of the epidermal growth factor receptor through p53. Carcinogenesis (2008) 1.33
Surface properties, more than size, limiting convective distribution of virus-sized particles and viruses in the central nervous system. J Neurosurg (2005) 1.31
Genome-wide RNAi screens in human brain tumor isolates reveal a novel viability requirement for PHF5A. Genes Dev (2013) 1.31
Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res (2011) 1.30
Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol (2009) 1.30
MET signaling regulates glioblastoma stem cells. Cancer Res (2012) 1.29
Genetic polymorphisms in GSTM1, -P1, -T1, and CYP2E1 and the risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev (2003) 1.28
Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol (2010) 1.27
EGFR-AKT-Smad signaling promotes formation of glioma stem-like cells and tumor angiogenesis by ID3-driven cytokine induction. Cancer Res (2011) 1.25
CXCR4 signaling regulates metastasis of chemoresistant melanoma cells by a lymphatic metastatic niche. Cancer Res (2010) 1.24
Cutaneous pigmentation after photosensitivity induced by vandetanib therapy. Arch Dermatol (2009) 1.23
Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiol Biomarkers Prev (2006) 1.23
Wnt activation is implicated in glioblastoma radioresistance. Lab Invest (2011) 1.22
Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol (2009) 1.21
FK506 binding protein mediates glioma cell growth and sensitivity to rapamycin treatment by regulating NF-kappaB signaling pathway. Neoplasia (2008) 1.21
Integration and analysis of genome-scale data from gliomas. Nat Rev Neurol (2011) 1.20
Polymorphisms in apoptosis and cell cycle control genes and risk of brain tumors in adults. Cancer Epidemiol Biomarkers Prev (2007) 1.17
Metronomic treatment of temozolomide inhibits tumor cell growth through reduction of angiogenesis and augmentation of apoptosis in orthotopic models of gliomas. Oncol Rep (2006) 1.15
A pilot study of metronomic temozolomide treatment in patients with recurrent temozolomide-refractory glioblastoma. Oncol Rep (2006) 1.15
A randomized, double-blind, placebo-controlled, phase 2 study of RMP-7 in combination with carboplatin administered intravenously for the treatment of recurrent malignant glioma. Neuro Oncol (2003) 1.15
Platelet-derived growth factor receptors differentially inform intertumoral and intratumoral heterogeneity. Genes Dev (2012) 1.15
Oxidative response gene polymorphisms and risk of adult brain tumors. Neuro Oncol (2008) 1.13
Phase II trial of low-dose continuous (metronomic) treatment of temozolomide for recurrent glioblastoma. Neuro Oncol (2010) 1.11
Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer (2008) 1.11
Prediction of Associations between microRNAs and Gene Expression in Glioma Biology. PLoS One (2011) 1.10
Splicing variant of AIMP2 as an effective target against chemoresistant ovarian cancer. J Mol Cell Biol (2012) 1.10
Clinical outcome of concomitant chemoradiotherapy followed by adjuvant temozolomide therapy for glioblastaomas: single-center experience. Clin Neurol Neurosurg (2009) 1.10
Determination of CC-5013, an analogue of thalidomide, in human plasma by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2004) 1.09
Agents with selective estrogen receptor (ER) modulator activity induce apoptosis in vitro and in vivo in ER-negative glioma cells. Cancer Res (2004) 1.09
Many tumors in one: a daunting therapeutic prospect. Cancer Cell (2011) 1.09
A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. Neuro Oncol (2011) 1.09
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09
A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol (2010) 1.08
Cancer-Specific requirement for BUB1B/BUBR1 in human brain tumor isolates and genetically transformed cells. Cancer Discov (2012) 1.07
Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date. Cancer (2014) 1.07
Invasion suppressor cystatin E/M (CST6): high-level cell type-specific expression in normal brain and epigenetic silencing in gliomas. Lab Invest (2008) 1.06
Genomic profiling combined with gene expression profiling in primary central nervous system lymphoma. Blood (2010) 1.06
Inhibition of platelet-derived growth factor receptor signaling restricts the growth of human breast cancer in the bone of nude mice. Clin Cancer Res (2005) 1.05
Correlation analysis between single-nucleotide polymorphism and expression arrays in gliomas identifies potentially relevant target genes. Cancer Res (2009) 1.04
Testing of new agents in childhood cancer preclinical models: meeting summary. Clin Cancer Res (2002) 1.03